Exploring Three High Growth Tech Stocks In The United States

In the last week, the United States market has been flat, yet it has seen a 20% increase over the past year with earnings projected to grow by 15% annually. In this context of robust growth potential, identifying high-growth tech stocks that align with these promising market conditions can be crucial for investors seeking opportunities in this dynamic sector.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Super Micro Computer	24.36%	24.28%	★★★★★★
Ardelyx	21.09%	55.29%	★★★★★★
AVITA Medical	33.20%	51.87%	★★★★★★
Alnylam Pharmaceuticals	21.62%	56.70%	★★★★★★
TG Therapeutics	29.48%	43.58%	★★★★★★
Alkami Technology	21.99%	102.65%	★★★★★★
Travere Therapeutics	30.52%	61.89%	★★★★★★
Clene	61.16%	59.11%	★★★★★★
Blueprint Medicines	23.52%	55.74%	★★★★★★
Lumentum Holdings	21.25%	118.58%	★★★★★★

Click here to see the full list of 231 stocks from our US High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

BioCryst Pharmaceuticals (NasdaqGS:BCRX)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: BioCryst Pharmaceuticals, Inc. is a biotechnology company that focuses on developing oral small-molecule and protein therapeutics for rare diseases, with a market cap of $1.81 billion.

Operations: BioCryst Pharmaceuticals generates revenue primarily from its biotechnology segment, specifically focusing on startups, with reported revenues of $412.58 million. The company is involved in the development of therapeutics for rare diseases.

BioCryst Pharmaceuticals, despite being unprofitable, is navigating a promising trajectory with an anticipated shift to profitability within three years. The company's recent guidance reveals a robust revenue uptick, projecting $540 million to $560 million for 2025, underpinned by a 36% year-on-year growth in 2024. This performance is bolstered by strategic product expansions like ORLADEYO, the first oral treatment for hereditary angioedema—now approved in 44 countries—which not only diversifies its portfolio but also enhances its market presence significantly.

• Dive into the specifics of BioCryst Pharmaceuticals here with our thorough health report.

• Review our historical performance report to gain insights into BioCryst Pharmaceuticals''s past performance.

Roku (NasdaqGS:ROKU)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Roku, Inc. operates a TV streaming platform both in the United States and internationally, with a market capitalization of approximately $12.34 billion.

Operations: Roku generates revenue primarily through its Platform segment, which includes advertising and content distribution, contributing $3.32 billion. The Devices segment, encompassing the sale of streaming players and audio products, adds $580 million to the total revenue.

Roku's strategic maneuvers, including its recent product launches and platform expansions, signal robust potential in the streaming sector. The introduction of QLED CHiQ Roku TVs in the UK and the expansion of The Roku Channel in Canada underscore its commitment to enhancing user experience and content accessibility. These initiatives align with an anticipated revenue growth of 10.7% per year, outpacing the US market average of 8.8%. Moreover, earnings are projected to surge by 53.84% annually, positioning Roku for a profitable pivot within three years amidst a competitive digital media landscape. This trajectory is supported by a positive free cash flow and strategic partnerships like FreeCast's integration on Roku’s platform, which broadens its advertising efficacy and content diversity.

• Get an in-depth perspective on Roku's performance by reading our health report here.

• Evaluate Roku's historical performance by accessing our past performance report.

Workday (NasdaqGS:WDAY)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Workday, Inc. offers enterprise cloud applications globally and has a market capitalization of $72.32 billion.

Operations: The company generates revenue primarily from its cloud applications segment, which brought in $8.16 billion. With a focus on enterprise solutions, it operates extensively both in the U.S. and internationally.

Workday's recent strategic alliances and client partnerships underscore its robust positioning in the tech sector, particularly within enterprise software solutions. Notably, its partnership with Nayya aims to revolutionize employee health and financial benefits through advanced data analytics integrated into the Workday platform. This initiative is set to enhance user engagement and decision-making efficiency, reflecting Workday's commitment to innovation in human capital management. Additionally, the company has shown impressive financial performance with a 2316% earnings growth over the past year and forecasts suggest a continued strong trajectory with expected annual revenue growth of 12.2% and earnings growth of 14.6%. These figures not only surpass general market trends but also highlight Workday’s effective strategy in expanding its technological capabilities and market reach through significant partnerships like those with Zuora for streamlined billing processes and TPA technologies for enhanced talent delivery systems.

• Click here to discover the nuances of Workday with our detailed analytical health report.

• Explore historical data to track Workday's performance over time in our Past section.

Make It Happen

• Reveal the 231 hidden gems among our US High Growth Tech and AI Stocks screener with a single click here.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com